Cannara Biotech Inc. announced details of its proposal to consolidate all of the issued and outstanding common shares of the company on the basis of ten pre-consolidation common shares for every one post-consolidation common shares, subject to the approval of shareholders at the upcoming meeting of shareholders (on January 25, 2023), as well as TSXV approval. The Board of Directors believes that the share consolidation will provide the company with greater flexibility in developing its plans.

Cannara Biotech Inc. is a Bristol Investor Relations client and a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Québec spanning over 1,650,000 square feet.

Read the full press release here: Cannara Announces Proposed Share Consolidation